

Correction

Correction: Liu et al. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. *Biomolecules* 2023, 13, 1179

Zhen Liu ^{1,†}, Xinyan Zhang ^{1,†}, Yanrong Wang ¹, Yifan Tai ¹, Xiaolin Yao ² and Adam C. Midgley ^{1,*} 

¹ State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials for the Ministry of Education, College of Life Sciences, Nankai University, Tianjin 300071, China

² School of Food and Biological Engineering, Shaanxi University of Science and Technology, Xi'an 710021, China

* Correspondence: midgleyac@nankai.edu.cn

[†] These authors contributed equally to this work.

There was an error in the original publication [1]. One of the reviewed peptides, THR-184, completed phase 2 clinical trials in 2017, but for a different disease treatment. A correction has been made to Section 5. Discussion and Future Perspectives, paragraph 4:

“Most of the peptides reviewed here are in the preclinical stage of development and have yet to enter clinical trials. THR-184 and ANG-3777 (an HGF peptide mimetic previously known as BB3) have both completed phase 2 clinical trials (ClinicalTrials.gov ID: NCT01830920; NCT02771509) as perioperative treatments in cardiovascular-surgery-associated acute kidney injury (CVS-AKI), which is a type of ischemic injury that may progress to chronic kidney disease and renal fibrosis [59,60].”

With this change, two more references were added: [59] and [60] (see [2,3]), and the original [59] and [60] have been modified to [61] and [62].

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.



Citation: Liu, Z.; Zhang, X.; Wang, Y.; Tai, Y.; Yao, X.; Midgley, A.C. Correction: Liu et al. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. *Biomolecules* 2023, 13, 1179. *Biomolecules* 2024, 14, 407. <https://doi.org/10.3390/biom14040407>

Received: 21 February 2024

Accepted: 29 February 2024

Published: 27 March 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

References

1. Liu, Z.; Zhang, X.; Wang, Y.; Tai, Y.; Yao, X.; Midgley, A.C. Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways. *Biomolecules* **2023**, *13*, 1179. [[CrossRef](#)] [[PubMed](#)]
2. Carlson, W.D.; Keck, P.C.; Bosukonda, D.; Carlson, F.R. A Process for the Design and Development of Novel Bone Morphogenetic Protein-7 (BMP-7) Mimetics with an Example: THR-184. *Front. Pharmacol.* **2022**, *13*, 864509. [[CrossRef](#)] [[PubMed](#)]
3. Ayad, S.; Neylan, J.F.; Mayne, T.J.; Gouveia, D.; Swaminathan, M. Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. *Kidney Int. Rep.* **2022**, *5*, 2325–2332. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.